Company: LGN
Filing Date: 2025-04-30
Form Type: DRS/A
Source: 0000950123-25-003868
Chunk: 304

Company: Legence Corp.
Filing Date: 2025-04-30
Form: DRS/A
Chunk 304
---
 |         4.3% |     | 3.8% |
| Expected volatility     |     |          75% |     |  55% |
| Expected life (years)   |     |          2.7 |     |  5.0 |

The hybrid method assumptions above for December 31, 2024 were based on the weighted average assumptions of potential future scenarios as follows:

|                         |     | Net Settle 
 at IPO (1) |     |      Remain as 
     Restricted 
       Series C 
         Common 
 Interests post 
        IPO (2) |     |  Delayed 
 Exit (3) |
| Expected dividend yield |     |        — % |     |            — % |     |      — % |
| Risk-free interest rate |     |       4.2% |     |           4.3% |     |     4.3% |
| Expected volatility     |     |        80% |     |            70% |     |      70% |
| Expected life (years)   |     |        0.5 |     |            3.5 |     |      5.0 |

| (1) | The Company completes an IPO, and Restricted Series C Common Interests are settled. |

| (2) | The Company completes an IPO, and Restricted Series C Common Interests remain outstanding. |

| (3) | The Company does not undergo a Change of Control in the foreseeable future. |

The compensation expense for liability-classified Restricted Series C Common Interests was as follows (in thousands):

|                                     |     | Year Ended December 31, | 2024 |     |   | 2023 |
|:------------------------------------|:----|:------------------------|-----:|:----|:--|-----:|
| Selling, general and administrative |     | $                       |  273 |     | $ |   15 |
| Cost of revenue                     |     |                         |  326 |     |   |   18 |
| Compensation expense                |     | $                       |  599 |     | $ |   33 |

F-48

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 Legence Holdings LLC and Subsidiaries Notes to Consolidated Financial Statements The stock-based compensation liability for Restricted Series C Common Inter